Summary of patient characteristics for the immunophenotype study
| Histology . | Age at biopsy (y) . | Node origin . | Sample age (mo) . | EBV status . |
|---|---|---|---|---|
| CHL (LR) | 35 | Cervical | 81 | + |
| CHL (MC) | 16 | Cervical | 149 | + |
| CHL (MC) | 31 | Cervical | 75 | + |
| CHL (MC) | 33 | Cervical | 49 | + |
| CHL (NK) | 23 | NK | 139 | NK |
| CHL (NS) | 38 | Cervical | 44 | − |
| CHL (NS) | 20 | Cervical | 82 | − |
| CHL (NS) | 28 | Cervical | 11 | − |
| CHL (NS) | 45 | Axilla | 31 | − |
| CHL (NS) | 23 | Cervical | 39 | − |
| CHL (NS) | 31 | Supraclav | 44 | − |
| CHL (NS) | 21 | Inguinal | 35 | − |
| CHL (NS) | 81 | Cervical | 119 | − |
| CHL (NS) | 24 | Cervical | 80 | − |
| CHL (NS) | 28 | Cervical | 149 | + |
| CHL (NS) | 40 | Cervical | 44 | + |
| CHL (NS) | 29 | Cervical | 46 | + |
| CHL (NS) | 18 | Cervical | 18 | NK |
| FH | 19 | Cervical | 23 | NA |
| FH | 68 | Cervical | 18 | NA |
| FH | 18 | Submental | 17 | NA |
| PH | 21 | Cervical | 18 | NA |
| PH | 73 | Cervical | 22 | NA |
| PH | 27 | Axilla | 5 | NA |
| Histology . | Age at biopsy (y) . | Node origin . | Sample age (mo) . | EBV status . |
|---|---|---|---|---|
| CHL (LR) | 35 | Cervical | 81 | + |
| CHL (MC) | 16 | Cervical | 149 | + |
| CHL (MC) | 31 | Cervical | 75 | + |
| CHL (MC) | 33 | Cervical | 49 | + |
| CHL (NK) | 23 | NK | 139 | NK |
| CHL (NS) | 38 | Cervical | 44 | − |
| CHL (NS) | 20 | Cervical | 82 | − |
| CHL (NS) | 28 | Cervical | 11 | − |
| CHL (NS) | 45 | Axilla | 31 | − |
| CHL (NS) | 23 | Cervical | 39 | − |
| CHL (NS) | 31 | Supraclav | 44 | − |
| CHL (NS) | 21 | Inguinal | 35 | − |
| CHL (NS) | 81 | Cervical | 119 | − |
| CHL (NS) | 24 | Cervical | 80 | − |
| CHL (NS) | 28 | Cervical | 149 | + |
| CHL (NS) | 40 | Cervical | 44 | + |
| CHL (NS) | 29 | Cervical | 46 | + |
| CHL (NS) | 18 | Cervical | 18 | NK |
| FH | 19 | Cervical | 23 | NA |
| FH | 68 | Cervical | 18 | NA |
| FH | 18 | Submental | 17 | NA |
| PH | 21 | Cervical | 18 | NA |
| PH | 73 | Cervical | 22 | NA |
| PH | 27 | Axilla | 5 | NA |
EBV status defined by LMP1 or EBER depending upon era of biopsy.
Median age patient (years) = 29/24/27. Median age SCS sample CHL/Reactive/PH (mo) = 48/18/18.
FH, follicular hyperplasia; LR, lymphocyte rich; MC, mixed cellularity; NK, not known; NS, nodular sclerosis; PH, paracortical hyperplasia.